NASDAQ: UTMD
UTAH MEDICAL PRODUCTS INCCIK 0000706698 · SIC 3841 · Surgical & Medical Instruments
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (MRSH 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade UTMD commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 12, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Consolidated Condensed Statements of Income
(in thousands, except per share amounts - unaudited)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Sales, net | 8,529 | 9,953 | 17,252 | 19,663 |
| Cost of goods sold | 3,771 | 4,358 | 7,212 | 8,530 |
| Gross profit | 4,758 | 5,595 | 10,040 | 11,133 |
| Operating expense | ||||
| Selling, general and administrative | 1,955 | 2,264 | 4,517 | 4,495 |
| Research & development | 154 | 135 | 308 | 289 |
| Total operating expenses | 2,109 | 2,399 | 4,825 | 4,784 |
| Operating income | 2,649 | 3,196 | 5,215 | 6,349 |
| Other income | 637 | 640 | 1,254 | 1,345 |
| Income before provision for income taxes | 3,286 | 3,836 | 6,469 | 7,694 |
| Provision for income taxes | 600 | 788 | 1,179 | 1,605 |
| Net income | 2,686 | 3,048 | 5,290 | 6,089 |
| Earnings per common share (basic) | 0.84 | 0.94 | 1.66 | 1.86 |
| Earnings per common share (diluted) | 0.84 | 0.94 | 1.66 | 1.86 |
| Shares outstanding basic | 3,184 | 3,246 | 3,184 | 3,278 |
| Shares outstanding diluted | 3,184 | 3,246 | 3,184 | 3,278 |
| Other comprehensive income (loss): | ||||
| Foreign currency translation net of taxes of $0 in all periods | (34) | 1,828 | (536) | 2,546 |
| Total comprehensive income | 2,652 | 4,876 | 4,754 | 8,635 |
| see notes to consolidated condensed financial statements | ||||
Consolidated Balance Sheets (Unaudited)
(in thousands, except per share amounts; mapped from filer XBRL tags, not printed on the filing face)
| Description | Jun 30, 2026 | Dec 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and equivalents | 87,528 | 85,756 |
| Accounts receivable, net | 3,565 | 3,522 |
| Inventories | 9,003 | 7,935 |
| Other current assets | 543 | 529 |
| Total current assets | 100,639 | 97,742 |
| Property, plant and equipment, net | 9,631 | 9,908 |
| Operating lease right-of-use assets, net | 286 | |
| Finite-lived intangible assets, net | 840 | |
| Identifiable intangible assets, net | 346 | 840 |
| Goodwill | 13,956 | 14,052 |
| TOTAL ASSETS | 124,572 | 122,542 |
| Current liabilities: | ||
| Accounts payable | 876 | 911 |
| Current portion of operating lease liabilities | 60 | |
| Accrued liabilities | 1,194 | 1,687 |
| Total current liabilities | 2,070 | 2,598 |
| Long-term debt | 195 | 225 |
| Operating lease liabilities | 226 | |
| Deferred income taxes and other liabilities | 274 | 337 |
| Total liabilities | 2,539 | 3,274 |
| Shareholders' equity: | ||
| Common stock | 32 | 32 |
| Capital in excess of stated value | — | — |
| Retained earnings (deficit) | 131,954 | 128,652 |
| Total shareholders' equity | 122,033 | 119,268 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 124,572 | 122,542 |
Consolidated Condensed Statements of Cash Flows
(in thousands - unaudited)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net income | 5,290 | 6,089 |
| Adjustments to reconcile net income to net cash provided by operating activities | ||
| Depreciation | 421 | 405 |
| Amortization | 478 | 1,048 |
| Provision for (recovery of) losses on accounts receivable | (12) | (7) |
| Amortization of Right-of-Use Assets | 30 | 26 |
| Deferred income taxes | (178) | (360) |
| Stock-based compensation expense | 192 | 168 |
| Tax benefit attributable to exercise of stock options | - | - |
| Changes in operating assets and liabilities: | ||
| Accounts receivable and other receivables | (56) | 409 |
| Inventories | (1,130) | 908 |
| Prepaid expenses and other current assets | (22) | 145 |
| Accounts payable | (34) | 37 |
| Accrued expenses | (487) | (1,531) |
| Total adjustments | (798) | 1,248 |
| Net cash provided by operating activities | 4,492 | 7,337 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Capital expenditures for: | ||
| Property and equipment | (264) | (235) |
| Net cash used in investing activities | (264) | (235) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Common stock purchased and retired | (206) | (6,708) |
| Payment of dividends | (1,976) | (2,018) |
| Net cash used in financing activities | (2,182) | (8,726) |
| Effect of exchange rate changes on cash | (274) | 827 |
| Net increase/(decrease) in cash and cash equivalents | 1,772 | (797) |
| Cash at beginning of period | 85,756 | 82,976 |
| Cash at end of period | 87,528 | 82,179 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||
| Cash paid during the period for income taxes | 1,660 | 2,327 |
| Cash paid during the period for interest | - | - |
| see notes to consolidated condensed financial statements | ||
Face scale: (in thousands, except per share amounts - unaudited); (in thousands - unaudited). Statements found on the EDGAR/iXBRL face print as filed; the rest are presentation-friendly mappings of filer XBRL tags, at the scale noted on each table. EPS as reported. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗